| 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and … B Williams, G Mancia, W Spiering, E Agabiti Rosei, M Azizi, M Burnier, ... European heart journal 39 (33), 3021-3104, 2018 | 14611 | 2018 |
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects JS Hulot, A Bura, E Villard, M Azizi, V Remones, C Goyenvalle, M Aiach, ... Blood 108 (7), 2244-2247, 2006 | 1239 | 2006 |
| 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by … G Mancia, R Kreutz, M Brunström, M Burnier, G Grassi, A Januszewicz, ... Journal of hypertension 41 (12), 1874-2071, 2023 | 676* | 2023 |
| Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial M Azizi, RE Schmieder, F Mahfoud, MA Weber, J Daemen, J Davies, ... The Lancet 391 (10137), 2335-2345, 2018 | 662 | 2018 |
| Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised … M Azizi, M Sapoval, P Gosse, M Monge, G Bobrie, P Delsart, M Midulla, ... The Lancet 385 (9981), 1957-1965, 2015 | 523 | 2015 |
| Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European … B Williams, G Mancia, W Spiering, E Agabiti Rosei, M Azizi, M Burnier, ... J Hypertens 36 (10), 1953-2041, 2018 | 508 | 2018 |
| Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the … B Williams, G Mancia, W Spiering, E Agabiti Rosei, M Azizi, M Burnier, ... J hypertens 36 (12), 2284-2309, 2018 | 490 | 2018 |
| Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension … R Kreutz, EAEH Algharably, M Azizi, P Dobrowolski, T Guzik, ... Cardiovascular research 116 (10), 1688-1699, 2020 | 447 | 2020 |
| Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. M Azizi, A Rousseau, E Ezan, TT Guyene, S Michelet, JM Grognet, ... The Journal of clinical investigation 97 (3), 839-844, 1996 | 415 | 1996 |
| First international consensus on the diagnosis and management of fibromuscular dysplasia HL Gornik, A Persu, D Adlam, LS Aparicio, M Azizi, M Boulanger, ... Vascular Medicine 24 (2), 164-189, 2019 | 365 | 2019 |
| Renin inhibition with aliskiren: where are we now, and where are we going? M Azizi, R Webb, J Nussberger, NK Hollenberg Journal of hypertension 24 (2), 243-256, 2006 | 340 | 2006 |
| Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II–renin … M Azizi, J Menard, A Bissery, TT Guyenne, A Bura-Riviere, ... Journal of the American Society of Nephrology 15 (12), 3126-3133, 2004 | 313 | 2004 |
| Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives M Azizi, G Chatellier, TT Guyene, D Murieta-Geoffroy, J Ménard Circulation 92 (4), 825-834, 1995 | 290 | 1995 |
| Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial B Williams, G Mancia, W Spiering, E Agabiti Rosei, M Azizi, M Burnier Rev Esp Cardiol 72 (2), 160, 2019 | 286 | 2019 |
| Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. BI Levy, JB Michel, JL Salzmann, M Azizi, P Poitevin, M Safar, ... Circulation Research 63 (1), 227-239, 1988 | 280 | 1988 |
| Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan JL Pool, RE Schmieder, M Azizi, JC Aldigier, A Januszewicz, W Zidek, ... American journal of hypertension 20 (1), 11-20, 2007 | 276 | 2007 |
| Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists M Azizi, J Ménard Circulation 109 (21), 2492-2499, 2004 | 252 | 2004 |
| Home blood-pressure monitoring in patients receiving sunitinib M Azizi, A Chedid, S Oudard New England Journal of Medicine 358 (1), 95-97, 2008 | 230 | 2008 |
| European consensus on the diagnosis and management of fibromuscular dysplasia A Persu, A Giavarini, E Touze, A Januszewicz, M Sapoval, M Azizi, ... Journal of hypertension 32 (7), 1367-1378, 2014 | 226 | 2014 |
| Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial M Azizi, K Sanghvi, M Saxena, P Gosse, JP Reilly, T Levy, LC Rump, ... The Lancet 397 (10293), 2476-2486, 2021 | 224 | 2021 |
